Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Paper Tigers Or Paper Bullets? FDA Cutting Down On Repeat GMP Warnings

This article was originally published in The Tan Sheet

Executive Summary

FDA enforcement policies being carried out by the Office of the Chief Counsel could eliminate the practice of issuing multiple manufacturing compliance warning letters

You may also be interested in...

Warning Letter Review By FDA Chief Counsel’s Office Will Take Five Days

FDA's Office of Chief Counsel will have five working days to review warning letters that previously were sent directly to manufacturers from district offices

Allen, Azar & Troy: FDA Legal Partners Streamline Enforcement Activity

HHS' decision to elevate FDA warning letter oversight from the Office of Regulatory Affairs to the Office of the Chief Counsel signals an attempt to keep a tighter rein on the agency in the absence of a commissioner

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts